The Union Budget 2026-27 lays emphasis on Scaling up manufacturing in 7 strategic and frontier sectors. While presenting the Union Budget 2026-27 in Parliament today, Union Minister of Finance & Corporate Affairs Smt Nirmala Sitharaman said that the proposed interventions forms part of six areas under ‘First Kartavya’ in the Budget.

To develop India as a global Biopharma manufacturing hub, the Budget proposes Biopharma SHAKTI with an outlay of ₹ 10,000 crores over the next 5 years. This will build the ecosystem for domestic production of biologics and biosimilars. The Strategy as envisaged in the Budget will include a Biopharma-focused network with 3 new National Institutes of Pharmaceutical Education and Research (NIPER) and upgrading 7 existing ones. It will also create a network of over 1000 accredited India Clinical Trials sites. The Union Budget proposes to strengthen the Central Drugs Standard Control Organisation to meet global standards and approval timeframes through a dedicated scientific review cadre and specialists.